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Objective To study the prevalence of and associated
factors for cognitive impairment and dementia in
community dwelling Chinese from Singapore.
Methods This study includes Chinese subjects from the
Epidemiology of Dementia in Singapore (EDIS) study,
aged ≥60 years, who underwent comprehensive
examinations, including cognitive screening with the
locally validated Abbreviated Mental Test and Progressive
Forgetfulness Questionnaire. Screen positive participants
subsequently underwent extensive neuropsychological
testing and cerebral MRI. Cognitive impairment no
dementia (CIND) and dementia were diagnosed
according to internationally accepted criteria. The
prevalence of cognitive impairment and dementia were
computed per 5 year age categories and gender. To
examine the relationship between baseline associated
factors and cognitive impairment, we used logistic
regression models to compute odd ratios with 95% CI.
Results 1538 Chinese subjects, aged ≥60 years,
underwent cognitive screening: 171 (15.2%) were
diagnosed with any cognitive impairment, of whom 84
were CIND mild, 80 CIND moderate and seven had
dementia. The overall age adjusted prevalence of CIND
mild was 7.2%; CIND moderate/dementia was 7.9%.
The prevalence increased with age, from 5.9% in those
aged 60–64 years to 31.3% in those aged 75–79 years
and 44.1% in those aged ≥80 years. Multivariate
analysis revealed age, diabetes and hyperlipidaemia to
be independently associated with cognitive impairment.
Conclusions In present study, the overall prevalence of
cognitive impairment and dementia in Chinese was
15.2%, which is in the same range as the prevalence
reported in Caucasian and other Asian populations.
INTRODUCTION
The population of Asia in 2009 was estimated at 4
billion, 59% of a global total of 6.8 billion.1 It is
expected that the proportion of older persons aged
≥60 years among the total Asian population will
rise from 10% in 2010 to 24% in 2050, and also
that the absolute number of elderly will dramatic-
ally increase from 414 million to 1.2 billion.2 As a
result of this rapid demographic aging, the burden
from common age related brain diseases, such as
dementia, is also expected to rise. The prevalence
of dementia in Asia has previously been found to
be lower than in western populations, but recent
studies suggest that age speciﬁc prevalence rates
may be similar.3
With respect to the Chinese population, preva-
lence estimates of dementia from China and
Singapore varied from 1.2% to 7.5% in those aged
>50 years.4 5 Moreover, in the past few decades
the focus has shifted towards the preclinical stages
of dementia, such as cognitive impairment no
dementia (CIND). Previous studies in Caucasian
populations reported a prevalence ranging from
14.9% to 22.2%, and in Asians, including Chinese,
around 7.7–22.2%.6 7 However, comparison
between studies is hampered due to differences in
case ascertainment, demographic factors and lack
of extensive neuropsychological testing.
In view of the limited knowledge of the preva-
lence of cognitive impairment among Asians, we
initiated a new population based study in Singapore
to investigate the prevalence and associated factors
of cognitive impairment in a Chinese population
from Singapore.
METHODS
Study design and study population
The Epidemiology of Dementia in Singapore
(EDIS) study comprised subjects from the ongoing
population based community dwelling study of
Chinese aged 40–85 years who participated in the
Singapore Chinese Eye Study (SCES). Of the 4605
eligible persons, a total of 3353 participated (par-
ticipation rate 72.8%). Ethics approval for the
EDIS study was obtained from the Singapore Eye
Research Institute and the National Healthcare
Group Domain Speciﬁc Review Board. The study
was conducted in accordance with the Declaration
of Helsinki. Written informed consent was
obtained, in the preferred language of participants,
by bilingual study coordinators prior to recruitment
into the study.
Participants in the SCES study were randomly
selected from the community and were invited to
the Singapore Eye Research Institute for interview
and clinical assessments, as described previously.8 9
Information on participants was collected by means
of a questionnaire, physical examination and
laboratory based tests. The questionnaire included
data on demographics, lifestyle factors, personal
and family health history, and medication use.
Physical examination included anthropometry,
blood pressure, pulse rate measurement and
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extensive eye examination, including digital fundal photography.
Laboratory examinations included serum creatinine, serum
lipids, plasma glucose, glycosylated haemoglobin and urine for
albumin and creatinine. Blood samples were stored for future
biomarker and genetic analysis.
In the ﬁrst phase of the EDIS study, SCES participants who
were ≥60 years old (n=1538) underwent cognitive screening
using the Abbreviated Mental Test and a self-report of progres-
sive forgetfulness, both of which have been previously validated
in Singapore.10–14 Screen positives were deﬁned as Abbreviated
Mental Test ≤6 among those with up to 6 years of formal edu-
cation or ≤8 among those with more than 6 years of formal
education, or if the subject or caregiver said yes to progressive
forgetfulness. Those who were screen negative were considered
to be cognitively normal. Screen positive subjects were invited
to participate in the second phase of the EDIS study.
Participants who declined the initial invitation were contacted
again at a later time. Those who declined at the ﬁrst attempt
were mailed study brochures, and offered free transportation
and pick up services. A person is termed ‘uncontactable’ if he/
she fails to respond after six attempts.
Examination procedures
During the second phase, participants underwent extensive clin-
ical and neuropsychological evaluation, along with laboratory
tests and neuroimaging, as detailed below (ﬁgure 1).
Questionnaire
A detailed questionnaire was administered by the interviewer to
collect relevant demographic and medical information. Data col-
lected included age, gender, education, marital status, occupa-
tion, ability to live independently, handedness, previous head
trauma, smoking, alcohol consumption and family history of
dementia. Previous medical history including stroke, cardiovas-
cular diseases, hypertension, hyperlipidaemia, diabetes mellitus,
vitamin B 12 deﬁciency, thyroid disease, urinary and bowel
incontinence, Parkinson’s disease, depressive symptoms and psy-
chiatric illnesses were noted, and subsequently veriﬁed by
medical records. The Instrumental Activities of Daily Living and
Barthel Activities of Daily Living indices were assessed for func-
tional status.15 16
Physical examination and clinical assessment
Clinical assessment included height, weight, blood pressure,
pulse rate, ankle brachial index, modiﬁed versions of the
National Institutes of Health Stroke Scale, Hachinski Ischaemic
Scale and frontal release signs. Clinical history, examinations
and Clinical Dementia Rating Scale evaluations were performed
by clinicians.
Blood tests
A total of 20 ml of blood were drawn in the fasting state. All
blood samples were sent to the National University Hospital
Laboratory for measurements on the same day. Blood tests
included: full blood count, glucose, lipids, creatinine, alanine
transaminase, aspartate transaminase, calcium, albumin, thyroid
function, vitamin B12, folate, syphilis screen, homocysteine and
high sensitivity C reactive protein.
Neuroimaging
MRI scans were performed on a 3 T Siemens Magnetom Trio
Tim scanner, using a 32 channel head coil, at the Clinical
Imaging Research Centre of the National University of
Singapore. A number of standardised and advanced MRI brain
sequences were performed to allow morphological, microstruc-
tural and functional assessments. Scanning time was approxi-
mately 60 min. Subjects with claustrophobia, contraindications
for MRI or those who are unable to tolerate the procedure
underwent a non-contrast enhanced CT scan, which was per-
formed in axial slices at 5 mm intervals rostrally from the orbi-
tomeatal line. Scanning time was approximately 3 min. There
were 17 subjects in total who had contraindications or refused
to undergo MRI, and instead underwent CT scan.
Cognitive impairment and dementia assessment
Neuropsychological test battery
Trained research psychologists administered brief cognitive
screening tests, the Mini-Mental State Examination and the
Figure 1 Flowchart of participants in the Epidemiology of Dementia in Singapore Study (EDIS). AMT, Abbreviated Mental Test; PFQ, Progressive
Forgetfulness Questionnaire.
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Montreal Cognitive Assessment, the Informant Questionnaire
on Cognitive Decline in the Elderly and a formal neuropsycho-
logical battery locally validated for Singaporean elderly.17 This
battery assesses seven domains, ﬁve of which are non-memory
domains.
The non-memory domains tested were:
▸ Executive function: Frontal Assessment Battery18 and
Maze Task19
▸ Attention: Digit Span, Visual Memory Span20 and
Auditory Detection21
▸ Language: Boston Naming Test22 and Verbal Fluency23
▸ Visuomotor speed: Symbol Digit Modality Test24 and
Digit Cancellation25
▸ Visuoconstruction: Weschler Memory Scale-Revised Visual
Reproduction Copy task,20 Clock Drawing26 and Weschler
Adult Intelligence Scale-Revised subtest of Block Design.27
The memory domains tested were:
▸ Verbal memory: Word List Recall11 and Story Recall
▸ Visual memory: Picture Recall and Weschler Memory
Scale-Revised Visual Reproduction.20
The assessment was administered according to the subject’s
habitual language and was completed in approximately 1 h. In
addition, we also performed the Geriatric Depression Scale,28
and the 12 item Neuropsychiatric Inventory29 was administered
to assess self-reported depressive symptoms and informant
reports on the presence, frequency, severity and resulting care-
giver distress associated with neuropsychiatric symptoms.
Diagnosis of cognitive impairment and dementia
Diagnoses of cognitive impairment and dementia were made at
weekly consensus meetings attended by study clinicians, neurop-
sychologists, clinical research fellows, research coordinators and
research assistants. Clinical features, blood investigations, psy-
chometrics and neuroimages were reviewed. Cognitive impair-
ment without dementia was deﬁned as impairment in at least
one domain of the neuropsychological test battery using educa-
tion adjusted cut-off values of 1.5 SDs below the established
normal means on individual tests. Failure in at least half of the
tests in a domain constituted failure in that domain. CIND mild
was diagnosed when ≤2 domains were impaired and CIND
moderate as impairment of >2 domains.
A diagnosis of dementia was made according to the DSM-IV
criteria. The aetiological diagnosis of Alzheimer’s disease was
made using the criteria for vascular dementia of the National
Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) and the National Institute of Neurological
Disorders and Stroke-Association Internationale pour la
Recherché et l’ Enseignement en Neurosciences (NINDS-
AIREN).30 Dementia severity was assessed using the Clinical
Dementia Rating Scale.
Associated factor assessment
The associated risk factors (age, gender, education, hyperten-
sion, diabetes, hyperlipidaemia, smoking, alcohol consumption,
low socioeconomic status, body mass index) were assessed
under standardised conditions. Systolic and diastolic blood pres-
sures were measured using a digital automatic blood pressure
monitor (OMRON-HEM 7203, Japan) after subject rested for
5 min. Blood pressure was measured twice, 5 min apart. The
mean of the two readings was considered the relevant blood
pressure. Hypertension was deﬁned as systolic blood pressure
≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg or
use of antihypertensive medications. Diabetes was deﬁned as
receiving treatment or glycated haemoglobin ≥6.5%.
Hyperlipidaemia was deﬁned as those on medications or total
cholesterol levels ≥4.14 mmol/l following the National
Cholesterol Education Programme Adult Treatment Panel III
guidelines. Education was categorised into no formal education
and formal education (≥ primary 1). Smoking was categorised
as non-smokers and smokers (past and current smokers).
Alcohol consumption was divided into non-drinkers and drin-
kers. A low socioeconomic status was deﬁned as a monthly
income <SGD2000. Body mass index was calculated as weight
(kg) divided by the square of height (m).
Statistical analysis
Statistical analysis was performed using standard statistical soft-
ware (Statistical Package for Social Science, SPSS V.19, SPSS Inc,
USA). To examine differences in associated factors between
screen positive subjects who participated in phase II and those
who did not, we used the Student’s t test for normally distribu-
ted continuous variables (body mass index), the Mann-Whitney
U test for skewed distributed continuous variables (age) and the
χ2 test for categorical variables. Crude and age adjusted preva-
lence of cognitive impairment and dementia were computed for
the whole cohort and within the strata of age and gender. Age
standardised rates were computed using world standard popula-
tion31 32 and CIs were calculated assuming that the prevalence
counts were Poisson distributed. To determine the relationship
between associated factors and cognitive impairment/dementia,
multiple logistic regression models were used, and ORs with
95% CI were computed. In model I, we included age, gender
and education, and each associated factor separately. In model
II, all the associated factors were included to examine whether
they were independently associated with cognition.
In order to include those screen positive subjects who did not
participate in phase II, we performed sensitivity analyses by
using different approaches. Two simple approaches assumed that
all screen positive non-responders were either all cognitively
normal (conservative approach) or impaired (liberal approach),
respectively. Finally, the third approach used was multiple
imputation that was taken to estimate the cognitive impairment
status of non-responders based on the data of the responders in
phase II. Multiple imputation by chain equations was used to
impute the missing values. Analysis of these multiple imputed
data consists of extracting the estimate and its SE from each ana-
lysis performed on an imputed completed dataset, and combin-
ing the multiple estimates and SEs to obtain a single estimate
and CI for the age standardised prevalence rates of cognitive
impairment and dementia. The linear regression model is used
to model missing continuous variables and logistic regression is
used to model missing categorical variables. For the multiple
imputation analysis, we performed 20 imputations. Finally, we
compared our gender speciﬁc prevalence estimates with those
reported from previous studies.
RESULTS
Screening and assessment of the Chinese cohort was performed
from 12 August 2010 to 10 February 2012. For those
≥60 years, participation rates for the ﬁrst phase were as follows:
73.6% (595/808) for 60–64 years, 70.8% (361/510) for
65–69 years, 70.5% (335/475) for 70–74 years, 55.8%
(173/310) for 75–79 years and 49.0% (74/151) for those aged
≥80 years. Of the 1538 subjects (mean age 68.9 years; range
60–85 years), 612 participants were screen positive. Of these,
300 subjects agreed to participate in phase II. Compared with
those who did not participate in phase II (n=312), those who
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participated were younger (mean age 69.9 years), more often
women, had a higher education and higher socioeconomic
status and were less often hypertensive, whereas the proportion
of hyperlipidaemia was higher (table 1). After excluding these
312 subjects, a total of 1226 subjects were available for the ana-
lysis (926 screen negatives and 300 screen positives). Mean age
of these 1226 subjects was 68.2 years (range 60–85 years).
Among these subjects, only 59 (4.9%) were >80 years of age.
Table 2 shows the crude and age standardised prevalence of
cognitive impairment. Among 1226 subjects, 171 participants
were diagnosed with cognitive impairment, of whom 84 (6.9%)
had CIND mild, 80 (6.5%) had CIND moderate and seven
(0.5%) had dementia. However, due to the small numbers,
dementia was combined with CIND moderate for further ana-
lyses. The crude prevalence of any cognitive impairment in the
population was 13.9%, with an age standardised prevalence rate
of 15.2% (95% CI 12.8 to 17.6).The age standardised preva-
lence of CIND mild was 7.2% (95% CI 5.6 to 8.8) and CIND
moderate/dementia 7.9% (95% CI 6.2 to 9.7). Prevalence
increased with age, from 5.9% in those aged 60–64 years to
31.3% in those 75–79 years and 44.1% in those aged
>80 years. In the present study, multivariate analyses revealed
Table 1 Baseline characteristics of screen positive participants in phase II compared with non-participants
Risk factors
Participated in phase II
Participants in phase I
Yes (n=300) (n=1538) No (n=312) p Value*
Age (years) 68.9 (60–85) 69.9 (60–85) 71.4 (60–85) 0.002
Gender (% women) 725 (47.1) 156 (52.0) 172 (55.1) 0.438
No formal education (% no) 600 (39.0) 144 (40.9) 171 (55) <0.001
Socioeconomic status (% low) 992 (64.5) 223 (63.4) 242 (77.8) <0.001
Diabetes (%) 333 (21.7) 96 (27.3) 77 (24.8) 0.462
Hyperlipidaemia (%) 807 (52.5) 271(77) 147 (47.3) <0.001
Hypertension (%) 1195 (77.7) 261 (74.1) 258 (83) 0.006
Smoking (% yes) 448 (29.1) 101 (28.7) 93 (29.9) 0.742
Alcohol drinking (% yes) 140 (9.1) 27 (7.7) 19 (6.1) 0.407
Body mass index (kg/m2) 23.6 (3.6) 23.8 (3.8) 23.5 (3.4) 0.217
*p Value for comparison between subjects who participated in phase II and those who did not.
Table 2 Prevalence of cognitive impairment and dementia both overall and stratified by age and gender
All persons Men Women
Age No n (%) No n (%) No n (%)
Any cognitive impairment
60–64 years 495 29 (5.9) 279 16 (5.7) 216 13 (6.0)
65–69 years 275 34 (12.4) 140 10 (7.1) 135 24 (17.8)
70–74 years 266 41 (15.4) 152 20 (13.2) 114 21 (18.4)
75–79 years 131 41 (31.3) 76 17 (22.4) 55 24 (43.6)
≥80 years 59 26 (44.1) 26 6 (23.1) 33 20 (60.6)
Crude 1226 171 (13.9) 673 69 (10.3) 553 102 (18.4)
Adjusted 15.2 (12.8–17.6)* 10.6 (7.8–13.3)* 19.9 (15.9–23.8)*
CIND mild
60–64 years 495 22 (4.4) 279 13 (4.7) 216 9 (4.2)
65–69 years 275 19 (6.9) 140 7 (5.0) 135 12 (8.9)
70–74 years 266 20 (7.5) 152 10 (6.6) 114 10 (8.8)
75–79 years 131 14 (10.7) 76 9 (11.8) 55 5 (9.1)
≥80 years 59 9 (15.3) 26 2 (7.7) 33 7 (21.2)
Crude 1226 84 (6.9) 673 41 (6.1) 553 43 (7.8)
Adjusted 7.2 (5.6–8.8)* 6.0 (4.1–8.0)* 8.3 (5.8–10.8)*
CIND moderate/dementia
60–64 years 495 7 (1.4) 279 3 (1.1) 216 4 (1.9)
65–69 years 275 15 (5.5) 140 3 (2.1) 135 12 (8.9)
70–74 years 266 21 (7.9) 152 10 (6.6) 114 11 (9.6)
75–79 years 131 27 (20.6) 76 8 (10.5) 55 19 (34.5)
≥80 years 59 17 (28.8) 26 4 (15.4) 33 13 (39.4)
Crude 1226 87 (7.1) 673 28 (4.2) 553 59 (10.7)
Adjusted 7.9 (6.2–9.7)* 4.5 (2.7–6.4)* 11.6 (8.5–14.6)*
*Age standardised rates (95% CI) compared with world standard population.
CIND, cognitive impairment no dementia.
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that age, gender, presence of diabetes and hyperlipidaemia were
independently associated with cognitive impairment (table 3).
Finally, we performed a sensitivity analysis for the prevalence
of cognitive impairment/dementia by including the screen
positive non-responders (n=312) using different approaches
(table 4). The two simple approaches revealed a broad range
(11.1–31.3%) for the prevalence of cognitive impairment/
dementia in this Chinese population. However, as these two
approaches reﬂect the two possible extremes, we used a third
more realistic approach using multiple imputation to estimate
the prevalence. This approach gave an overall prevalence of cog-
nitive impairment/dementia of 24.3%. Trends for cognitive
impairment across age and gender were the same as those found
when we performed the initial analyses excluding the screen
positive non-responders. Figure 2 shows our overall and gender
speciﬁc prevalence estimates in relation to those reported from
previous studies on cognitive impairment. Our prevalence esti-
mates were comparable with those described in other studies.
DISCUSSION
In this population based study among Singaporean Chinese aged
≥60 years, the prevalence of all cognitive impairment was
15.2%, with CIND mild accounting for 7.2% and CIND mod-
erate/dementia for 7.9%. The prevalence of cognitive impair-
ment increased from 5.9% in those aged 60–64 years to 44.1%
in those aged ≥80 years. The most important associated factors
were age, diabetes and hyperlipidaemia.
Some limitations of our study should be noted. Firstly, nearly
half of the screen positives declined to take part in phase II.
Therefore, our prevalence estimate was probably an
underestimation. In order to evaluate the robustness of our
prevalence estimates and obtain an indication of the ‘true’
prevalence, we performed a sensitivity analysis by including the
312 screen positive non-responders using different approaches,
including multiple imputation, to estimate their cognitive status
in phase II. This approach suggests that the true prevalence may
be around 24% in this Chinese population. Secondly, due to the
relatively few cases of dementia, we were not able to study
dementia separately. Furthermore, we were unable to examine
the associated factors of dementia subtypes due to the small
numbers. Thirdly, because of the cross sectional design of the
study, it was not possible to make causal inferences with respect
to the relationship we found between the associated factors and
cognitive impairment. Finally, the small number of subjects and
a relatively low participation rate for those >75 years of age (in
particular >80 years of age) limited us in extrapolating our ﬁnd-
ings to these age groups.
The strengths of the study include the following: subjects in
the EDIS study were drawn from a population based study;
extensive neuropsychological examination for diagnosing cogni-
tive impairment and dementia; and standardised procedures to
collect data on baseline associated factors.
Comparison of our study in terms of the prevalence of cogni-
tive impairment with other Caucasian and Asian studies is chal-
lenging due to differences in the selection of study populations,
demographic differences between populations (such as age dis-
tributions), differences in clinical criteria used and disparity in
the deﬁnitions of cognitive impairment. A recent systemic
review included all of the population based studies from 1984
and 2008 which examined the prevalence of cognitive
Table 4 Sensitivity analysis on the prevalence of cognitive impairment and dementia by including the 312 non-responders at phase II (n=1538)
Age standardised rates (95% CI)
Approach Type of impairment All persons Men Women
Non-respondents: not cognitively impaired Any cognitive impairment 11.1 (9.4 to 12.9) 8.3 (6.2 to 10.4) 13.8 (11.1 to 16.5)
Non-respondents: cognitively impaired Any cognitive impairment 31.3 (28.4 to 34.2) 25.4 (21.7 to 29.1) 37.1 (32.7 to 41.5)
Multiple imputation Any cognitive impairment 24.3 (21.6 to 27.0) 18.6 (15.1 to 22.1) 29.8 (25.7 to 34.0)
Multiple imputation CIND mild 11.4 (9.4 to 13.4) 10.0 (7.2 to 12.9) 12.7 (9.6 to 15.7)
Multiple imputation CIND moderate/dementia 12.9 (10.6 to 15.2) 8.5 (5.8 to 11.2) 17.2 (13.5 to 20.8)
CIND, cognitive impairment no dementia.
Table 3 Association between baseline risk factors and cognitive impairment, expressed as OR with corresponding 95% CI
CIND mild (n=84) CIND moderate/dementia (n=87)
Risk factors Model I* Model II† Model I* Model II†
Age (years) 1.08 (1.04 to 1.12) 1.11 (1.05 to 1.18) 1.18 (1.13 to 1.22) 1.17 (1.12 to 1.21)
Gender (women vs men) 1.06 (0.69 to 1.63) 0.90 (0.50 to 1.53) 2.37 (1.44 to 3.88) 2.18 (1.16 to 4.12)
No formal education 1.81 (1.16 to 2.84) 1.93 (1.09 to 3.40) 1.46 (0.89 to 2.41) 1.04 (0.58 to 1.86)
Low socioeconomic status 1.13 (0.63 to 2.03) 1.13 (0.61 to 2.07) 2.16 (1.04 to 4.45) 2.04 (0.96 to 4.31)
Diabetes 1.48 (0.92 to 2.39) 1.85 (1.11 to 3.05) 1.97 (1.18 to 3.30) 2.11 (1.23 to 3.61)
Hyperlipidaemia 2.32 (1.44 to 3.74) 2.85 (1.70 to 4.77) 3.08 (1.75 to 5.39) 3.22 (1.82 to 5.67)
Hypertension 0.66 (0.40 to 1.08) 0.64 (0.37 to 1.11) 1.00 (0.52 to 1.93) 0.91 (0.46 to 1.79)
Smoking 1.03 (0.60 to 1.77) 0.93 (0.52 to 1.65) 1.52 (0.80 to 2.89) 1.34 (0.68 to 2.60)
Alcohol drinking 1.30 (0.57 to 2.96) 1.15 (0.48 to 2.67) 1.15 (0.43 to 3.09) 0.99 (0.35 to 2.72)
Body mass index 0.98 (0.89 to 1.08) 0.95 (0.80 to 1.10) 0.99 (0.89 to 1.10) 0.98 (0.88 to 1.11)
*Model I included age, gender, education and each associated factor separately.
†Model II included age, gender, education, low socioeconomic status, diabetes, hyperlipidaemia, hypertension, smoking, alcohol drinking and body mass index.
CIND, cognitive impairment no dementia.
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impairment.33 Since the publication of this review, one add-
itional study from Spain has also reported prevalence estimates
for cognitive impairment.34 Figure 2 summarises the studies
from this review, which reported age adjusted prevalence esti-
mates together with our own prevalence estimates. Figure 2
shows that the reported prevalence of cognitive impairment has
a wide range, from 1.03% to 28.3%, and that the prevalence
estimate from the EDIS is intermediate. In our study, the preva-
lence estimate in women (20%) was higher compared with men
(11%), which is in accordance with ﬁndings from previous studies.
As this is probably an underestimation, our imputed prevalence of
24.3% suggests that the true prevalence among Singaporean
Chinese may be towards the higher end of this range. Speciﬁcally,
with respect to Asian studies among subjects who were 65 years
and older, a study from Japan reported an overall crude prevalence
of 10.8%35 whereas another study from Taiwan showed a crude
prevalence of 22.2%.7 However, a direct comparison with our
study is not possible as they presented only crude estimates and
did not use extensive neuropsychological assessment for the diag-
nosis of cognitive impairment and dementia.
With respect to associated factors for cognitive impairment,
we found a large difference in the prevalence of cognitive
impairment between genders, with women nearly twice as likely
of having cognitive impairment.36 37 Apart from gender, we
found that age, and those with diabetes and hyperlipidaemia
were more likely to have cognitive impairment. These ﬁndings
are in accordance with ﬁndings from previous studies.
In conclusion, this study showed an overall prevalence of
15.2% for cognitive impairment and dementia in a Chinese
population in Singapore, which is in accordance with data from
other Caucasian and Asian studies. These data further underline
the fact that future research should focus on the preclinical
stages of dementia, not only in Caucasian, but equally so in
Asian populations. Future studies, including those with a longi-
tudinal design, are required to establish risk factors for the
development of these preclinical stages and progression of cog-
nitive impairment to dementia.
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